FOXO4-DRI

46-residue D-retro-inverso FOXO4–p53 interaction research peptide · cell and mouse evidence only

Lot-specific chromatographic purity and quantitative peptide content; confirm identity, stereochemistry and both values on the released-lot COA · target, verify batch COACAS 2460055-10-9RUO

Research statusCell and mouse evidence; no established human clinical evidence; laboratory Research Use Only

Supplied form46-residue all-D retro-inverso FOXO4-derived peptide fused to a retro-inverso HIV-TAT cell-penetrating segment

Lead time14–21 days

FOXO4-DRI — Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA

FOXO4-DRI — Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research applications include FOXO4–p53 protein-interaction assays, senescent-versus-control cell models, caspase and p53-localisation studies, D-retro-inverso peptide design, and controlled replication in ageing or chemotoxicity models
Mouse or cell outcomes are research observations, not anti-ageing or therapeutic product benefits.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 2460055-10-9
Formula: C₂₂₈H₃₈₈N₈₆O₆₄
Molecular weight: 5358 g/mol
Appearance: Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA
Purity: Lot-specific chromatographic purity and quantitative peptide content; confirm identity, stereochemistry and both values on the released-lot COA · target, verify batch COA
Storage: Follow the released-lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, container and prepared-solution hold time require evidence for the exact 46-residue form, matrix and concentration; avoid unvalidated freeze–thaw handling.
MOQ: On request
Lead time: 14–21 days

PubChem CID 167312269

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about FOXO4-DRI

FOXO4-DRI is a 46-residue all-D retro-inverso fusion peptide designed to interfere with the FOXO4–p53 interaction and enter cells through a retro-inverso HIV-TAT-derived segment. PubChem CID 167312269 lists formula C₂₂₈H₃₈₈N₈₆O₆₄, molecular weight 5358 g/mol and CAS 2460055-10-9. The original 2017 work reported selected senescent-cell apoptosis and mouse-model outcomes; subsequent evidence remains preclinical. Unverified listings for a 12-residue, approximately 1,612 Da material under CAS 1883545-51-6 are not alternate forms of this 46-residue product.

Sequence, stereochemistry and analytical qualification
FOXO4–p53 interaction studies; senescent-versus-control cell assays; p53 localisation and caspase readouts; and controlled mouse-model replication
These are research applications, not clinical indications.

Mechanism context

The question the literature is testing

The primary 2017 study reported that FOXO4-DRI competes with FOXO4 for p53 binding, promotes nuclear exclusion of active p53 and induces caspase-3/7-dependent apoptosis preferentially in selected senescent cell models. Selectivity varied by model and does not mean universal recognition of all senescent cells or safety for normal tissues. Long-term consequences of manipulating FOXO4/p53 biology in humans are unknown.

Evidence map

Research routes and exposure context

Evidence tierMixed evidence context

Research areaLongevity research

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not for human or veterinary use
Cell selectivity and short mouse studies do not establish human safety, immunogenicity, biodistribution, tumour risk, reproductive safety or effects of repeated FOXO4/p53 modulation
Community injection reports are not safety evidence
Follow the released-lot SDS and institutional controls.

Interactions reported in the literature

No controlled human combination or drug-interaction programme exists
Claims involving rapamycin, quercetin, corticosteroids, dasatinib, Humanin, chemotherapy, MOTS-c, Epitalon, 5-Amino-1MQ or BPC-157 are not validated patient compatibility or safety guidance.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

FOXO4-DRI factory batch COAs

FOXO4-DRI 2 mg Factory batch COA protected preview

FOXO4-DRI2 mg · WHJLP-FOXO42-260511-B

FOXO4-DRI 10 mg Factory batch COA protected preview

FOXO4-DRI10 mg · WHJLP-FOXO410-260511-B

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require the full 46-residue sequence, all-D stereochemistry, termini, TAT-derived segment, free-base or salt assignment, theoretical and observed high-resolution intact mass, orthogonal sequence evidence, stability-indicating HPLC purity and impurity profile, quantitative peptide content, counterion/water/residuals and lot-specific stability
Sterility and endotoxin are separate tests
A generic ≥99% area result cannot detect every deletion, stereochemical or sequence error.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

FOXO4-02MG2 mg10 vials

FOXO4-10MG10 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released-lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, container and prepared-solution hold time require evidence for the exact 46-residue form, matrix and concentration; avoid unvalidated freeze–thaw handling.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Identity: PubChem CID 167312269 and the 46-residue all-D sequence reported in the primary and 2025 structural papers. Foundational evidence: Baar et al., Cell 2017, PMID 28340339 and PMCID PMC5556182. Follow-up preclinical context includes the aged-mouse Leydig-cell study, PMCID PMC7053614; human-chondrocyte in-vitro study, PMCID PMC8116695; 2025 structural study, PMCID PMC12216184; and 2026 endothelial-cell study, PMID 41625068. Every outcome must retain its exact cell or mouse model; none establishes human efficacy or dosing.

01
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Cell · 2017 · peer-reviewed original research (landmark/foundational)
Open source
02
Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
Frontiers in Bioengineering and Biotechnology · 2021 · peer-reviewed original research
Open source
03
FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway
Journal of Cellular and Molecular Medicine · 2022 · peer-reviewed original research
Open source
04
FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice
Naunyn-Schmiedeberg's Archives of Pharmacology · 2023 · peer-reviewed original research
Open source
05
FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
Aging (Albany NY) · 2020 · peer-reviewed original research
Open source
06
FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells
Experimental Gerontology · 2024 · peer-reviewed original research
Open source
07
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
Nature Communications · 2025 · peer-reviewed original research
Open source
08
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
Communications Biology · 2025 · peer-reviewed original research
Open source

Product FAQ

Questions buyers ask about FOXO4-DRI

What does D-retro-inverso mean for FOXO4-DRI identity?+

The sequence order is reversed relative to the parent L-peptide and the residues are D-amino acids, aiming to preserve side-chain topology while changing backbone orientation and protease susceptibility. For this product, confirm all-D stereochemistry, the complete 46-residue sequence, termini, TAT-derived segment, free-base or salt form and observed intact mass. A product name or short fragment is not equivalent.

FOXO4-DRI

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about FOXO4-DRI

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

FOXO4-DRI factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes

FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway

FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice

FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice

FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells

The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI

FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation

Questions buyers ask about FOXO4-DRI

Compare adjacent molecules and documentation needs.

Epithalon

MOTS-c (Human)

PNC-27